Citations

Showing 10 of 108152 citations.

TRPPing up bronchiectasis
Mercado‐Perez, Arnaldo , Beyder, Arthur

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | September 11, 2019 | Volume: 317 | Issue: 4 | Pages: L464-L465

10.1152/ajplung.00363.2019 | PMID 31508977 Get It

Experience With a Research and Innovation Office to Support Laboratory Medicine and Pathology Research
Beinborn, Julie, Saling, Kenneth, Reed, Katelyn A. , Ibrahim, Mohamed , Feldman, Andrew L.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2019 | Volume: 152 | Issue: Supplement_1 | Pages: S99-S99

10.1093/ajcp/aqz119.001 Get It

Abstract Objectives Translational research in laboratory medicine and pathology is transforming health care based on recent quantum advances in omics technologies, computational science, and precision medicine. However, high-volume clinical settings where this research may be most effective often have significant constraints on faculty time that challenge productivity. The objective of this study was to assess our experience with a new resource designed to address this challenge. Methods In September 2016, we established the Research and Innovation Office (RIO) in the Department of Laboratory Medicine and Pathology, Mayo Clinic–Rochester. The goal was to provide infrastructure to unburden faculty from performing administrative, organizational, and operational tasks related to research. Over 30 months, we solicited faculty input into desired services, conducted surveys on utility and ease of use, and tracked metrics, including faculty participation, numbers of projects, and publications. Results Faculty members were highly satisfied with the range of services, ease of use, and service-oriented approach of RIO. Initial services included project organization, institutional process support (eg, IRB protocol management), biospecimen requests and handling, and data management. Based on early feedback, patient consenting, budget support, and manuscript assistance were added as additional services. Total RIO staff increased from 6 to 10 during in the first 30 months. Over this time, 97 of 160 faculty members (60%) utilized RIO services in over 1,000 discrete project requests. Annual departmental publications increased by 50% during this time. Conclusion Faculty time is a critical element for translational research productivity in laboratory medicine and pathology departments. Numerous tasks previously performed by faculty could be managed effectively by a team of research facilitators that unburdened constraints on research time and led to high levels of faculty engagement, satisfaction, and productivity. This model may promote advances in transformative laboratory medicine and pathology research in high-volume clinical settings.
Improving Patient Value Through Cross-Country Collaboration
Yip, Tameson, Ramsower, Colleen , Glinsmann‐Gibson, Betty, Robetorye, Ryan S. , Ford, Jennifer, Rimsza, Lisa M.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2019 | Volume: 152 | Issue: Supplement_1 | Pages: S126-S126

10.1093/ajcp/aqz124.006 Get It

Abstract Introduction Lymph2Cx lymphoma cell-of-origin assay (LM2CX) was developed by the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) to better categorize diffuse large B-cell lymphoma (DLBCL). NanoString has licensed the assay and is currently pursuing FDA approval. In the meantime, the test is offered exclusively as a lab-developed test (LDT) by the Mayo Clinic Molecular Diagnostics–Arizona Lab (MDAZL) to Mayo Clinic Enterprise patients. In order to comply with these restrictions, the normal workflow for Mayo Clinic Rochester has been modified as cases are sent to Arizona. Rochester consultants order LM2CX using their local laboratory information system (LIS). Slides are prepared by Rochester histology and then shipped to Arizona, where they are entered into the Arizona LIS and processed. In July 2018, we discovered numerous cases that were ordered but not shipped. Because this step took place at the LIS transition between Arizona and Rochester, it was not detected immediately. Methods Allied Health Staff (AHS) colleagues in Rochester and Arizona had the unique opportunity to collaborate. After Arizona AHS identified the problem, they reached out to the Rochester pathology reporting specialists (PRSs) and began a joint improvement project. Together, we were able to measure the impact of the problem, with Arizona auditing digitally, while Rochester audited physical cases. We found 29% of the cases were handled improperly over a 6-month time period. In order to eliminate the gap, Rochester implemented several improvements, including training, tagging all LM2CX cases, and huddle discussions, while Arizona AHS monitored the process digitally. Results Since implementation of improvements, we have had zero defects. Modifications to AHS/consultant training in Rochester will ensure continued success. Conclusions This intervention illustrates the importance of strong collaborations in order to quickly respond to testing issues and provide the greatest value to patients.
Improving Augmented Human Intelligence to Distinguish Burkitt Lymphoma From Diffuse Large B-Cell Lymphoma Cases
Mohlman, Jeffrey S., Leventhal, Samuel , Pascucci, Valerio , Salama, Mohamed E.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2019 | Volume: 152 | Issue: Supplement_1 | Pages: S122-S122

10.1093/ajcp/aqz123.000 Get It

Abstract Introduction Our objective is to improve the assistive role of a deep, densely connected convolutional neural network (CNN) to hematopathologists in differentiating histologic images of Burkitt lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL). We hypothesized that for the majority of cases, a CNN would accurately differentiate BL from DLBCL and attempted to identify design and input variables to improve performance. Methods and Materials In total, 3608 images of BL were collected from 18 cases and 2,071 images of DLBCL were collected from 20 cases using Aperio Image Scope (Leica Biosystems, Buffalo Grove, IL). Cases were randomized into training and unknowns, and three separate CNNs were trained and applied to unknown images. Networks differed by either the size in pixels of the images (network 1 used 32 × 32 while networks 2 and 3 used 224 × 224) or absence of color (in network 2). Decreased numbers of training images were used to evaluate network 3. Results Network 3 performed the best with 17 of 19 (89%) cases classified correctly, 10 with 100% of images correct. Overall, network 3 had 88% accuracy, 80% precision, 81% recall, and an F1 score of 0.81. Receiver operating characteristic (ROC) curve analysis showed an area under the curve (AUC) of 0.89 for DLBCL and 0.88 for BL. Networks 1 and 2 performed more poorly with F1 scores of 0.63 and 0.39, respectively. Decreasing training images by one-half and one-fourth resulted in decreased F1 scores of 0.63 and 0.60, respectively. Conclusions CNNs are promising augmented human intelligence tools for differentiating DLBCL from BL cases and potentially could contribute to improved workflow in the laboratory. More training images, larger image size, and color significantly improved performance of the CNN because of the added information available to the network. More research is under way to optimize the performance of CNNs’ lymphoma application.
Interventions for uterine fibroids: an overview of Cochrane Reviews
Brito, Luiz Gustavo Oliveira , Chaim, Sarah O Olivi, Stewart, Elizabeth A. , Chaim, Sarah Olivi, Martins, Wellington P. , Farquhar, Cindy M. , Brito, Luiz Gustavo Oliveira

Mayo Clinic

Cochrane Database of Systematic Reviews | September 11, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/14651858.cd013426 Get It

Real-Time Detection of Analytical Outliers on the Roche Troponin T Generation 5 Assay
Wockenfus, Amy M., Hartung, Katherine J., Kelley, Brandon, Katzman, Brooke M. , Jaffe, Allan S. , Karon, Brad S. , Donato, Leslie J. , Jaffe, Allan S.

Mayo Clinic

American Journal of Clinical Pathology | September 11, 2019 | Volume: 152 | Issue: Supplement_1 | Pages: S83-S83

10.1093/ajcp/aqz116.007 Get It

Abstract Introduction Analytical outliers occur with most troponin assays and can adversely affect patient management. We developed a system to detect analytical outliers for the Roche Troponin T (cTnT) Gen 5 assay using repeat analysis of samples manifesting changing values over 2 to 6 hours. Methods In our ED practice, troponins are collected at baseline, 2 hours, and at times at 6 hours in plasma separator tubes and processed on the Roche Cobas e411 (Indianapolis, IN). When troponin values change by ≥10 ng/L or ≤10 ng/L in the 2- or 6-hour sample compared to baseline, the sample that produced the result is repeated. If initial and repeat values differ by > ±5 ng/L (cTnT <100 ng/L) or ±5% (cTnT ≥100 ng/L), the initial value is deemed to be an analytical outlier. Outliers are confirmed by a third measurement. Results Since March 2018, 19 of 17,154 (0.11%) troponin samples analyzed have been labeled outliers. Outliers were falsely elevated in 14 cases and falsely decreased in 5. Mean (range) of initial cTnT values for outliers was 39 ng/L (18-621 ng/L), with only one initial value >100 ng/L. All changes could affect analysis of change over time. Eleven of 19 outliers were outside gender-specific reference interval on both samples and thus did not cause a change from abnormal to normal. Repeat measurements on 8 of 19 outliers were within the URL, which may have greater clinical consequences. Conclusions Repeat analysis upon observation of changing values allows detection of analytical outliers in real time, prior to reporting results. These outliers are almost always clinically significant in terms of interpretation of changing values and at times change patients from above to below the URL. If we tested more than just changing samples, we might detect still more outliers.
Dominant collagen XII mutations cause a distal myopathy
Mohassel, Payam , Liewluck, Teerin , Hu, Ying , Ezzo, Daniel, Ogata, Tracy, Saade, Dimah , Neuhaus, Sarah , Bolduc, Véronique , Zou, Yaqun , Donkervoort, Sandra , Medne, Līvija , Sumner, Charlotte J. , Dyck, P. James B. , Wierenga, Klaas J. , Tennekoon, Gihan, Chen, Jiani , Winder, Thomas , Staff, Nathan P. , Foley, A. Reghan , Koch, Manuel , Bönnemann, Carsten G. , Liewluck, T , Staff, Nathan P , Finkel, Richard S. , Winder, Thomas L., Donkervoort, Sandra

Mayo Clinic

Annals of Clinical and Translational Neurology | September 11, 2019 | Volume: 6 | Issue: 10 | Pages: 1980-1988

10.1002/acn3.50882 | PMID 31509352 Get It

AbstractObjectiveTo characterize the natural history and clinical features of myopathies caused by mono‐allelic, dominantly acting pathogenic variants in COL12A1.MethodsPatients with dominant COL12A1‐related myopathies were characterized by history and clinical examination, muscle imaging, and genetic analysis. Pathogenicity of the variants was assessed by immunostaining patient‐derived dermal fibroblast cultures for collagen XII.ResultsFour independent families with childhood‐onset weakness due to novel, dominantly acting pathogenic variants in COL12A1 were identified. Adult patients exhibited distal‐predominant weakness. Three families carried dominantly acting glycine missense variants, and one family had a heterozygous, intragenic, in‐frame deletion of exon 52 of COL12A1. All pathogenic variants resulted in increased intracellular retention of collagen XII in patient‐derived fibroblasts as well as loss of extracellular, fibrillar collagen XII deposition. Since haploinsufficiency for COL12A1 is largely clinically asymptomatic, we designed and evaluated small interfering RNAs (siRNAs) that specifically target the mutant allele containing the exon 52 deletion. Immunostaining of the patient fibroblasts treated with the siRNA showed a near complete correction of collagen XII staining patterns.InterpretationThis study characterizes a distal myopathy phenotype in adults with dominant COL12A1 pathogenic variants, further defining the phenotypic spectrum and natural history of COL12A1‐related myopathies. This work also provides proof of concept of a precision medicine treatment approach by proposing and validating allele‐specific knockdown using siRNAs specifically designed to target a patient’s dominant COL12A1 disease allele.
Size‐Dependent Vulnerability of Lumbar Motor Neuron Dendritic Degeneration in SOD1 G93A Mice
Fogarty, Matthew J. , Mu, Erica W. H. , Lavidis, Nickolas A., Noakes, Peter G. , Bellingham, Mark C. , Fogarty, Matthew J , Bellingham, Mark C , Fogarty, Matthew J

Mayo Clinic

The Anatomical Record | September 11, 2019 | Volume: 303 | Issue: 5 | Pages: 1455-1471

10.1002/ar.24255 | PMID 31509351 Get It

ABSTRACT The motor neuron (MN) soma surface area is correlated with motor unit type. Larger MNs innervate fast fatigue‐intermediate (FInt) or fast‐fatiguable (FF) muscle fibers in type FInt and FF motor units, respectively. Smaller MNs innervate slow‐twitch fatigue‐resistant (S) or fast fatigue‐resistant (FR) muscle fibers in type S and FR motor units, respectively. In amyotrophic lateral sclerosis (ALS), FInt and FF motor units are more vulnerable, with denervation and MN death occurring for these units before the more resilient S and FR units. Abnormal MN dendritic arbors have been observed in ALS in humans and rodent models. We used a Golgi‐Cox impregnation protocol to examine soma size‐dependent changes in the dendritic morphology of lumbar MNs in SOD1 G93A mice, a model of ALS, at pre‐symptomatic, onset and mid‐disease stages. In wildtype control mice, the relationship between MN soma surface area and dendritic length or dendritic spine number was highly linear (i.e., increased MN soma size correlated with increased dendritic length and spines). By contrast, in SOD1 G93A mice, this linear relationship was lost and dendritic length reduction and spine loss were observed in larger MNs, from pre‐symptomatic stages onward. These changes correlated with the neuromotor symptoms of ALS in rodent models. At presymptomatic ages, changes were restricted to the larger MNs, likely to comprise vulnerable FInt and FF motor units. Our results suggest morphological changes of MN dendrites and dendritic spines are likely to contribute ALS pathogenesis, not compensate for it. Anat Rec, 303:1455–1471, 2020. © 2019 American Association for Anatomy
Microbiology of Implant-Based Breast Reconstruction Infections
Banuelos, Joseph, Vyas, Krishna S. , Sohail, M. Rizwan , Sharaf, Basel , Sohail, M Rizwan , Abu‐Ghname, Amjed , Asaad, Malke , Sharaf, Basel A

Mayo Clinic

Annals of Plastic Surgery | September 11, 2019 | Volume: 85 | Issue: 2 | Pages: 194-201

10.1097/sap.0000000000001974 | PMID 31513083 Get It

Background Postsurgical complications have been an increasing concern for hospitals, particularly in light of payment reform. The costs to the health care system are increasing in light of Medicare penalties for readmissions for certain conditions. Surgical site infection following implant-based breast reconstruction (IBR) remains challenging. The rates of positive cultures and isolated microorganisms in IBR are unknown. This systematic review summarizes the reported microorganisms and positive culture rates in the existing literature. Methods A systematic review was performed using the guidelines outlined in Preferred Reporting Items for Systematic Reviews and Meta-analyses. Articles were included if breast implant infection rates and culture results were reported. Further subgroup analysis of culture positive infections was performed. Results A total of 25 studies were included, encompassing 25,177 IBR. Implant infections were reported in 1356 reconstructions (5.4%). Cultures were positive in 74.5% of infections. Gram-positive bacteria were the most common (68.6%), of which Staphylococcus species (51%) was the most isolated pathogen, followed by Pseudomonas. A subgroup analysis showed that early infections (63% vs 88%), radiotherapy (82% vs 93%), and acellular dermal matrix use (90% vs 100%) were associated with lower positive culture rates than their respective counterparts. Patients who received chemotherapy had higher positive culture results (94% vs 83%). Isolated microorganisms also varied among the subgroups. Conclusions This systematic review outlines reported microorganisms in IBR. Staphylococcus species and Pseudomonas were the most frequently reported microorganism. Negative cultures were reported in up to 25.5% of infections. Patients with early infections, radiotherapy, and acellular dermal matrix demonstrated higher negative culture rates. This review can help guide the use of empirical antimicrobial therapy in IBR.
Appalachian Status Is a Negative Predictor of Breast Reconstruction Following Breast Cancer Resection
DeCoster, Ryan , Burns, Jack C., Shrout, Max A., Wetzel, Margaret, Rinker, Brian, Butterfield, Timothy A. , Vásconez, Henry C., Rinker, Brian D, Stout, Megan A. , Dugan, Adam Joseph , Webster, J. Matthew

Mayo Clinic

Annals of Plastic Surgery | September 11, 2019 | Volume: 83 | Issue: 6 | Pages: e15-e19

10.1097/sap.0000000000001965 | PMID 31513081 Get It

Background Health care disparities in Appalachia are well documented. However, no previous studies have examined possible differences in the utilization of breast reconstruction (BR) in Appalachia. This study aims to determine if a disparity in BR utilization exists in women from Appalachia Kentucky. Methods A retrospective, population-based cohort study was conducted from January 1, 2006, to December 31, 2015. The Kentucky Cancer Registry was queried to identify population-level data for female patients diagnosed with breast cancer and treated with mastectomy. A multivariate logistic regression model controlling for patient, disease, and treatment characteristics was constructed to predict the likelihood of BR. Results Bivariate testing showed differences (P < 0.0001) in BR utilization between Appalachian and non-Appalachian women in Kentucky (15.0% and 26.3%, respectively). Multivariate analysis showed that women from Appalachia (odds ratio, 0.54; confidence interval (95), 0.48–0.61; P < 0.0001) were less likely to undergo BR than non-Appalachian women. Interestingly, the rate of BR increased over time in both Appalachian (r = 0.115; P < 0.0001) and non-Appalachian women (r = 0.148; P < 0.0001). Conclusions Despite the benefits of BR, women from Appalachia undergo BR at lower rates and are less likely to receive BR than non-Appalachian Kentuckians. Although the rates of BR increased over time in both populations, access to comprehensive breast cancer care remains a challenge for women from Kentucky's Appalachian region.